The lung, like most other organs, is susceptible to injury by circulating immune complexes, and also by humoral autoantibody and immune lymphocytes which specifically recognize selected lung antigens. In addition, by virtue of its direct communication with the external environment, the lung can also be injured by inhaled environmental agents which trigger inflammatory reactions mediated by immune effector systems. Although major emphasis to date has been placed on the ability of inhaled antigens to first sensitize, then provoke, immunologically specific reactions in the lung, there is increasing evidence to show that these same immune effector systems are also triggered in an immunologically nonspecific fashion by a certain environmental agents (termed "mitogens") which activate leukocytes in a polyclonal fashion. Such agents include certain viruses and other microorganisms, bacterial endotoxin, a wide variety of plant lectins, and certain chemicals, such as the phorbol esters. Although such agents act in an immunologically nonspecific fashion, they are nonetheless quite specific from a chemical viewpoint, and in many cases act by binding to specific receptors on the cell surface. By activating macrophages directly, and by activating much larger percentages of a given lymphocyte population than do specific antigens, they induce correspondingly amplified inflammatory reactions in vivo. Recent studies with animal models indicate that inhaled mitogens are strikingly effective in inducing pulmonary inflammation, whereas inhaled antigens (lacking mitogenic activity) produce little if any parenchymal injury in immunized recipients, unless administered in conjunction with a mitogen. Ongoing studies using such models promise to provide valuable new insight into the biologic properties which govern the pathogenicity of inhaled environmental agents, the mediators they release, and the biochemical basis for variations in individual susceptibility to injury by such agents.
Introduction
The association between inhalation of organic dusts and the development of chronic pulmonary disease has been recognized for centuries (1) . However, whereas the actions of such dusts have traditionally been considered to be a nonspecific "toxic" effect, advances in our understanding of tissue inflammation have led to revised, more detailed hypotheses concerning mechanisms of tissue injury. Studies of environmental lung disease have been particularly influenced by related advancements in pulmonary immunology and immunopathology, perhaps best exemplified by the delineation of IgE-mediated allergic asthma (an airway disorder which will not be discussed in this paper), and the production of pulmonary hemorrhage and acute glomerulonephritis by antibasement membrane antibodies in patients with Goodpasture's syndrome (2) .
Currently, there is considerable interest in immunologic mechanisms which may be responsible for environmental lung diseases associated with dust inhalation. Such studies were prompted largely by Pepys (3) patients with farmer's lung contained precipitating antibody against the causative agent, Micropolyspora faeni. Subsequently, a number of environmental lung diseases, characterized by the presence of precipitating serum antibody against pathogenic dust antigens, have been described (4) . Pepys proposed that these pulmonary diseases, which he termed "extrinsic allergic alveolitis" have also been known as "hypersensitivity pneumonitis," result from local formation of pathogenic immune complexes composed of inhaled antigen and humoral antibody.
There are serious objections to such a straightforward immune complex hypothesis, however, as Pepys himself noted (5) . First, it has been well established that many, if not most, individuals who inhale these pathogenic dusts develop humoral antibodies to dust antigens but fail to develop evidence of disease (6) . Second, there is little if any obvious relationship. between the magnitude or specificity of individual immune responses to dust antigens and the extent of pulmonary disease (7) . This is in contrast to the cutaneous Arthus reaction and other immune complex-mediated phenomena. Third, whereas virtually all dust antigens, when inhaled, stimulate production of specific host antibody (8, 9) , only selected antigens (e.g., pigeon droppings) appear to be pathogenic; other equally antigenic, osten-sibly similar antigens (e.g., chicken droppings) seldom if ever cause allergic alveolitis (5) . Pepys (5) has thus further proposed that immune complex injury occurs in association with a more rapidly developing, immediatetype hypersensitivity response which potentiates subsequent immune complex formation. Interestingly, however, Pepys (10) has noted that patients with allergic alveolitis are notably nonatopic, and that these immediate-type hypersensitivity reactions are not mediated by IgE-class antibody.
Subsequently, several alternative hypotheses have been proposed which, in essence, identify both cellular and humoral mechanisms as the prime cause of lung injury (7); such hypotheses have been based largely on demonstrations of cellular as well as humoral immunity to dust antigens in patients with allergic alveolitis. As with Pepys' original hypothesis, however, they fail to account for the differential pathogenicity of various dust antigens, and also the poor correlation between test measurements of host immunity and the severity of lung disease. In fact, many now believe that host immunity to environmental dust antigens merely reflects a history of exposure.
Clinical data also suggest that noninfectious parenchymal lung diseases other than allergic alveolitis may also be immunologically mediated; both fibrosing alveolitis (11) and Wegener's granulomatosis (12) , for example, have been ascribed to immune complex-type reactions. Moreover, immune complexes have been identified in the circulation of a variety of patients with active interstitial pneumonitis (but not end-stage fibrosis), including patients with "idiopathic" interstitial inflammation, as well as in patients with other known immune complex-mediated connective tissue disorders (13) .
Yet a new dimension has been recently added to our understanding of "immunologic" disorders, namely, the recognition that both the cellular and humoral effector systems can also be triggered through immunologically nonspecific mechanisms, as, for example, the acute respiratory distress syndrome caused by nonimmune activation of complement in patients undergoing extracorporeal dialysis (14) . This paper will not attempt to outline the entire spectrum of human lung diseases thought to be immunologically mediated, nor will it review in detail all known immune effector systems, but rather it will concentrate on recent advances in our understanding of how immune effector systems might be activated in the lung. In particular, we will highlight the potential role of environmental and endogenous cell activators, emphasizing the pathogenic consequences associated with the release of certain inflammatory mediators by activated lung cells.
Immune Effector Systems
Immunologic tissue injury is mediated through activation of one or more effector systems. Immunologic specificity exists only during the recognition and binding of antigen to antigen-specific lymphocyte receptors or immunoglobulin combining sites. Such initial reactions are not of great pathological moment in themselves, but serve to trigger cellular and humoral effector systems (such as macrophages and complement, respectively). These systems, through a process of self-activation and self-amplification, generate soluble inflammatory mediators, which recruit and activate additional leukocytes. When fully developed, such a process constitutes a true inflammatory nidus, recognized clinically and histologically.
Although the activation of the immune effector systems in such instances is immunologically specific in nature, the effector systems themselves function in an immunologically nonspecific fashion. These effector/ amplification systems are, moreover, controlled and regulated by discrete inhibitor systems, including betaadrenergic agonists, E-series prostaglandins and histamine (15) , and in the lung, surface-active materials as well (16) . Depending on the site and manner in which effector systems are activated (and regulated), they may serve either to protect the host or to cause tissue injury and disease.
Immune effector systems comprise both humoral and cellular elements, and attempts to characterize immunologic disorders as being one or the other in nature constitute an artificial distinction. For example, effector mechanisms associated with "cellular" reactions (such as the tuberculin skin reaction) are mediated in part by soluble factors; indeed, certain "humoral" factors, such as complement, are produced by activated monocytes and macrophages (17) . Traditionally, humoral immune effector mechanisms have included the complement, kinin and coagulation systems. The latter two systems will not be considered further, and the reader is referred to several excellent reviews which discuss these areas in depth (18, 19) .
Complement
Activation of the complement system is characterized by the sequential proteolytic cleavage of complement protein components, thereby converting inactive precursor forms into biologically active fragments (Fig. 1) . While the complement components are typically found in the plasma, they can also be synthesized locally by macrophages (1 7) , indicating that complement-mediated reactions could theoretically occur in the lung air spaces in the absence of other humoral constituents. However, studies by Reynolds et al. (20) argue against such a possibility by showing that ratios of complement components to serum albumin, as measured in human bronchopulmonary lavage fluid, are lower than those in serum. Among the biologic activities associated with these fragments are: increases in vascular permeability (C3a; C5a), contraction of smooth muscle (C3a; C5a), enhanced phagocytosis (C3b;), leukocyte chemotaxis (C5a) and cell lysis (C5b-9). These biologic activities are in turn controlled not only through spontaneous decay, where biologic activity decreases spontaneously with time, but also through the action of serum inhibitors, such as the Cl-esterase inhibitor, C3b inactivator and 31H (21, 22) . Absence of the Cl-esterase inhibitor is associated with episodes of laryngeal edema (hereditary angioneurotic edema) (23) , while the inability of the C3b inactivator and f1H control protein to effectively regulate the formation of the alternative pathway C3-cleaving enzyme, BbC3b (due either to a C3b inactivator deficiency, or to the binding of an autoantibody to the C3bBb complex), is associated with a hypocomplementemic form of glomerulonephritis (24) .
The complement cascade can be activated by two major pathways. The "classical" pathway is initiated by binding and -activation of the Clq,r,s assembly, leading in turn to sequential activation of C4, C2, C3 and C5-9. The "alternative" pathway bypasses the Cl, C4 and C2 steps, utilizing instead factors B and D plus properdin, C3, and C5-9 (25) . Immune . Another important aspect of the complement system is that it is activated via an enzymatic cascade, with proteolytic cleavage of precursor components yielding enzymatically active fragments which, in turn, cleave (and "activate") succeeding components. By virtue of its enzymatic nature, the overall reaction is, in effect, amplified. In particular, generation of the intermediate, C3b, constitutes a major amplifying step in the alternative pathway by acting through a positive feedback loop (see Fig. 1 ).
Lymphokines and Monokines
A number of cell-derived mediators have also been characterized in vitro. In some cases, these mediators exist as preformed substances within the cell (e.g., histamine within mast cell granules) and are released into the extracellular environment following an appropriate stimulus. In other cases, stimulation of the cell leads first to mediator synthesis, then release (e.g., lymphokine production by lymphocytes). The number of biologic activities generated by activated cells is very large; a partial list is given in Table 1 . The lymphokines, which at first were thought to be released exclusively by T-(thymus dependent) lymphocytes, are now known to be produced, in some cases, by B-(bone marrow-derived) lymphocytes as well (e.g., migration inhibitory factor) (27) . Only some of these mediators have been characterized physicochemically as yet, and it is possible that, in some instances, different biologic activities may in fact represent different manifestations of the same molecule.
Soluble mediators released by activated lymphoid cells include Interleukin 1 (IL-1; also known as "lymphocyte activating factor"), Interleukin 2 (IL-2; also known as "T-cell growth factor"), "mitogenic factor," "macrophage activating factor" and chemotactic factors, which act in concert to attract, then activate other leucocytes in an immunologically nonspecific fashion. These mediators constitute an important amplifying mechanism and, as in the case of the complement cascade, enable the host to mount a sizeable inflammatory response following a relatively trivial but immunologically specific initiating reaction. In classic studies by McCluskey et al. (28) and later by Cohen et al. (29) , immune cell participation in delayed-type hypersensitivity reactions was examined in recipients passively sensitized with radiolabeled lymphocytes. These studies demonstrated that virtually all lymphocytes present at the inflammatory site were in fact "nonimmune" (i.e., they were of host origin). Presumably, such cells were recruited (and activated) by amplifying mediators. IL-1 is of particular interest since it provides one of the macrophage-derived signals necessary for both the induction as well as the expression of the immune response. In addition, it also is required for T-cell responses to mitogens, and its ability to greatly amplify such responses constitutes the basis for the IL-1 assay (30) . Its role in the production of inflammatory lung disease seems certain since alveolar macrophages, when activated, produce IL-1 in large amounts, and since IL-1 also appears to be identical to endogenous pyrogen (31) . In the case of rabbit alveolar macrophage IL-1, we have shown the production of two distinct species possessing molecular weights of 14,400 and 11,600 daltons, and isoelectric points of 4.6 and 7.4, respectively (32) . Recently, IL-1 has also been reported to cause fibroblasts to proliferate (33) , and synovial cells to secrete collagenase (34) . Thus, this single mediator, produced by alveolar macrophages, helps establish immunity to antigenic substances, facilitates activation of cellular immune effector system by both antigens and mitogens, produces fever, and may lead to pulmonary fibrosis.
As in the complement system, in which component proteins exist as inactive precursor forms and become biologically active only following enzymatic cleavage, cell-derived mediator synthesis and/or release typically occurs only following activation of the cell by an appropriate stimulus. This can occur in an immunologically specific fashion, as when antigen binds to receptors on immune T-lymphocytes, or to antigen binding sites of homocytotropic antibody on the surface of basophils. It can also occur, however, as a consequence of immunologically nonspecific cell activation by a variety of agents termed "mitogens" or "polyclonal cell activators" (35) (see discussion of activation systems). Among the cell activators known to trigger lymphokine and monokine production by lymphocytes and macrophages are plant lectins, microorganisms and their constituents (including LPS), and certain chemicals and enzymes (see Table 2 ). Polyclonal cell activators can also trigger basophils to release vasoactive amines (36) which, in turn, promote tissue inflammation by enhancing passage of other humoral and cellular effectors out of the blood vessels and into the interstitial spaces.
Platelet-Activating Factor
IgE-coated basophils, when stimulated with specific antigen, release not only vasoactive amines directly, but also platelet-activating factor (PAF) which, in turn, causes release of additional vasoactive amines from platelets. PAF, a potent, biologically active lipid recently identified as acetyl glyceryl ether phosphorylcholine (AGEPC) (37) , is also released by stimulated monocytes, neutrophils, mast cells and, of particular relevance to this discussion, alveolar as well as peritoneal macrophages (38) . In vivo studies in experimental animal models have shown that PAF, when injected intravenously, causes depletion of circulating neutrophils, basophils and platelets, with pulmonary platelet sequestration (39) , increases vascular permeability, promotes immune complex deposition in serum sickness (40) and causes bronchoconstriction (41) . It has been further suggested that variations in PAF release from alveolar macrophages reflect different states of activation of these cells (38) . 
Arachidonic Acid Metabolites
A fourth major immune effector system consists of a family of lipidlike mediators which are generated through metabolism of arachidonic acid, derived from membrane phospholipids by the actions of phospholipases (42) . These mediators, in turn, can be subdivided into products of the cyclooxygenase pathway (including prostaglandins, prostacyclin and thromboxanes), and those produced through the lipoxygenase pathway (leukotrienes, including B4 and SRS-A; HPETEs and HETEs) (Fig 2) . Both classes of oxygenation products are known to be synthesized in the lung, primarily by alveolar macrophages (43) .
The prostaglandins have been studied extensively in vitro and in vivo, often by blocking their production by aspirin and indomethacin, which inhibit cyclooxygenase. Potentially, they can function both as effectors and regulators of inflammation in vivo, but their precise role in tissue inflammation is somewhat difficult to define since different products may have opposing biologic activities. Moreover, they may be produced simultaneously, but in different quantities, and may have different biologic half-lives. Nevertheless, the well-known antiinflammatory actions of aspirin almost certainly results from inhibition of cyclooxygenase activity in vivo. Interestingly, the lung not only is an important site for prostaglandin synthesis, it also is a major site for inactivation of certain prostaglandins (44) . Arachidonic oxygenation products ofthe lipoxygenase pathway, on the other hand, are relatively insensitive to the action of the nonsteroidal anti-inflammatory drugs. SRS-A ("slow-reacting substance ofanaphylaxis"), which is known to play a role in anaphylaxis, has been shown to be leukotrienes C4 and D4 (45) . The chemotactic and degranulating properties of certain HETE molecules (46) as well as leukotriene B4 suggest that they, too, may play a role in immunologic lung disease.
Oxygen-Derived Free Radicals
Last, a fifth effector system has recently emerged which may be important in parenchymal lung disease, and which involves the extracellular release of oxygenderived free radicals, particularly H202, OH and 02-, by stimulated neutrophils and macrophages. These radicals are known to be important mediators of both the intracellular killing of phagocytized microorganisms and, in some cases, the extracellular killing of tumor cells by macrophages (47) . They have been implicated in both the direct cutaneous Arthus reaction (48) as well as a reverse passive Arthus reaction produced in the lung (49) , since inflammation associated with these reactions can be blocked by introduction of enzymatic "scavengers" capable of rapidly inactivating oxygen free radicals. In vitro studies by Jacob and co-workers (50) should be emphasized, however, that these systems exist in normal as well as diseased individuals, and are, in fact, primarily protective for the host (52) . Whether a particular system acts to benefit the host or, instead, cause disease is determined by the conditions of activation, especially the nature of the initiating signal, as well as by the effectiveness of relevant control or regulating mechanisms in modulating and, eventually, terminating the effector system once activated.
Immunologically Specific Mechanisms
The "classical" means by which immune effector systems are activated is through interaction of antigen with specific antibody or sensitized lymphocytes. In the case of immunologically mediated diseases, these interactions can be further subdivided into (a) reactions directed against antigens which are immunologically unrelated to the target organ affected, and (b) reactions directed against one or more antigens intrinsic to the organ structure. Examples of the first case include lung injury associated with circulating antigen-antibody complexes arriving via the circulation which become localized or "trapped" in the lung, or by complexes forming in situ between inhaled antigens and circulating (or locally synthesized) antibody An example of the second case is the formation of autoantibodies, specific for capillary basement membrane antigens, and which, when they bind in vivo, cause pulmonary hemorrhage and glomerulonephritis (Goodpasture's syndrome). While sometimes described as an example of a "cytotoxic" mechanism (53) , such injury in fact appears to result from damage to the extracellular basement membrane, presumably through local release of proteolytic enzymes (54) and, possibly, oxygen radicals.
Antigens can also activate immune lymphocytes, either by binding to cell membrane antibody (B-cells) or by interacting with immunologically specific T-cell membrane receptors. B-cell activation typically leads to B-cell proliferation and differentiation, accompanied by synthesis and release of specific antibody and certain lymphokines as well (27) . Stimulation of T-cells results in lymphokine release, cell proliferation and differentiation. While antibody production per se does not necessarily result in tissue inflammation, local release of lymphokines probably does.
Immunologically Nonspecific Mechanisms
Yet another means by which immune effector systems can be activated is through the actions of mitogens, also known as "polyclonal cell activators," which activate nonimmune lymphocytes, macrophages, basophils, mast cells and complement in an immunologically nonspecific fashion (35, 55) . Best studied of these mitogens are the plant lectins, phytohemagglutinin (PHA) and concanavalin A (Con A), which bind to specific sugar moieties or "receptors" on cell surfaces. When they bind to T-lymphocytes, they further initiate a sequence of biochemical and morphological events which transform the cell from a "resting" state to an "activated" one in which the cells increase in size, synthesize new enzymes, produce and secrete lymphokines, undergo blastogenesis and cell division and, ultimately, acquire differentiated cell functions such as cytotoxic capabilities (35) . Since these effects parallel those induced in "immune" T-cells by specific antigen, these lectins came to be widely used for in vitro studies of cell-mediated immunity. In this regard, they offered notable advantages over the use of antigen in that: they were effective on cells from "immunologically-naive" (i. e., not previously immunized) donors; by acting on lymphocytes in a polyclonal fashion, they activated larger numbers of lymphocytes than did specific antigen, thereby exaggerating the in vitro responses; and mitogens were useful in defining subsets of lymphocytes, based on their ability or failure to respond to a particular mitogen.
Subsequently, T-cell mitogens have been used to simulate cell-mediated or delayed-type hypersensitivity reaction in vivo as well, first in the skin, and subsequently in the lung and other organs (56, 57) . However, as yet little consideration has been given to the possible role of mitogens per se as a cause of environmental lung disease in man, although experimental studies have clearly demonstrated that mitogens are capable of causing a rapidly developing pneumonitis by themselves and, under certain circumstances, triggering immune complex reactions leading to pulmonary fibrosis. (57) . Moreover, the list of known mitogens presently includes viruses, bacteria (and LPS), thermophilic Micropolyspora, enzymes and chemicals (Table 2 ), many of which are known to cause human disease; it is apparent that they may do so partly through their ability to activate nonimmune lymphocytes in a polyclonal fashion. Moreover, it is further possible that patients predisposed to inflammatory lung disease may be unable to regulate responses to local mitogenic stimulation in a proper fashion.
The association between a1-antiprotease deficiencies and a propensity to inflammatory lung disease (including fibrosing alveolitis) is well known. It is particularly interesting, then, to note that a1-antiprotease has been shown to inhibit lymphocyte activation by T-cell mitogens (58, 59) . We have extended these observations by showing that a1-antiprotease inhibits IL-1 activity, including both its T-cell activating properties as well as its ability to stimulate fibroblast proliferation (60, 61) . In addition, certain proteases (including trypsin), which are inhibited by a1-antiprotease, are known to be B-cell mitogens (35 (88) , and heterologous serum (89) have been used. Antigen challenge has been administered by aerosol inhalation (82, 84, 90) , direct intrapulmonary instillation (65), or even transtracheal injection (86) , resulting in injury patterns ranging from pulmonary consolidation (63) to a neutrophil-rich intraalveolar hemorrhage (65) , to no injury at all (82) .
No general agreement has been reached concerning the mechanism(s) involved. Fried (63) immunofluorescence staining in lung tissues from monkeys sensitized passively with antibody, then challenged with antigen aerosol; similar findings were observed by Santives et al. (91) in the guinea pig. By prior decomplementation with cobra venom factor, Roska et al. (92) were able to prevent injury in ovalbumin-immunized guinea pigs challenged with ovalbumin aerosols. Johnson and Ward (65) also demonstrated a requirement for complement and neutrophils in the reverse passive Arthus model, and further suggested a role for oxygen-derived free radicals in the production of such injury (49) .
In contrast, other investigators have failed to detect evidence of immune complex injury in lungs of immunized rabbits challenged with M. faeni (93) or BSA (82) .
Thft et al. (94) were unable to prevent injury induced by BSA aerosols in sensitized rabbits by prior de-complementation, while Moore et al. (88) actually observed an inverse relationship between complement consumption and injury following challenge with a pigeon dropping extract. In one study, Santives et al (91) reported that IgE antibody serves to trigger immune complex disease; however, most studies to date have failed to demonstrate a role for homocytotropic antibody in these models (87, 88, 92 injections of complete Freund's adjuvant (91) , or intravascular injections of killed BCG organisms (88) . The latter two approaches, while effective, may be of questionable relevance to human disease; the potential role of inhaled mitogens, on the other hand, may be particularly relevant. The ability of humoral antibody or sensitized lymphocytes to passively sensitize test animals to subsequent injury by aerosol challenge has been studied in several laboratories. Adoptive sensitization using serum antibody has been achieved successfully in some instances (89, 95) , but not others (94, 96) . Transfer of sensitized cells has been reported to render the guinea pig susceptible to inhalation injury (97); Wilkie et al. (87) found that either cells or serum worked satisfactorily. Bice et al. (98) were able to adoptively sensitize rabbits to subsequent aerosol challenge by giving intraperitoneal injections of allogeneic lymphoid cells (but not serum) obtained from immunized donors. Other cell-transfer techniques, carried out in outbred animals, have experi- FIGURE 6 . Pulmonary histopathology in a BSA-immunized rabbit challenged with BSA aerosol. The small, solitary focus of granulomatous, interstitial inflammation, seen in the lower left, is characteristic of the widely scattered, almost trivial lesions occasionally present in rabbits immunized with BSA in alum depots, and challenged for three consecutive days with BSA aerosols, 100 mg BSA/day (estimated total pulmonary uptake is 480 ,ug BSA). H&E; x 60.
enced technical difficulties due apparently to histocompatibility differences between donor and recipient or to rapid antibody production by the transferred cells (89). Willoughby and co-workers, in developing an animal model of environmental lung disease, have employed an aerosol challenge system in which antigens and mitogens can be administered to (and inhaled by) rabbits under precisely defined conditions (82) . The uptake, organ distribution and fate of these proteins in vivo has been quantitatively determined by radiolabeling procedures, while their anatomic localization within the lung has been observed directly by labeling them with fluorescein. Under the standardized conditions employed, one can estimate the total body uptake of inhaled protein as a function of the amount nebulized (Fig. 4) . Using a modification of the paired isotope system to correct for plasma label, they have measured the organ sequestration of inhaled protein as a function of time following aerosol administration (Fig. 5 ). While at least 10% of the inhaled protein initially reaches the lung, most is eventually cleared into the gastrointestinal tract and digested. The degraded peptides (which no longer react with anti-BSA antibody) are absorbed into FIGURE 7 . Interstitial pulmonary inflammation induced by three daily administrations of Con A aerosol (estimated total pulmonary uptake is 480 ,g ConA). H&E; x 110.
the circulation, where they reach maximal concentrations at 24 hr post-aerosol (82) . By 48 hr post-aerosol, all protein has been degraded, and the radiolabel excreted into the urine. The presence of host immunity to the inhaled protein does not significantly affect the fate of this protein in vivo (82) . The fate of intrapulmonary antigen is critically dependent on the experimental conditions under which it is introduced, however (99). For example, direct instillation of antigen-containing solutions into the lung (82,100)-or insufflation of antigen aerosols into extirpated perfused lungs (101)-results in release of intact antigen into the circulation, due possibly to alterations in tight junctions of cellular barriers (102) . Using this defined aerosol administration system, it was next demonstrated that administration of antigen (BSA) aerosols to immunized rabbits (possessing circulating antibody to BSA following repeated intramuscular injections of BSA in alum) induced only minimal pulmonary inflammation (Fig. 6) ; no injury was observed in previously unimmunized recipients, even following repeated (biweekly) aerosol challenges which, by themselves, eventually induced high titers of circulating anti-BSA antibody (1 mg/mL) after several weeks (82) .
In contrast, administration of T-cell mitogens (Con A or PHA) in aerosol form induces a diffuse interstitial pneumonitis characterized by interstitial edema and mixed inflammatory infiltrates in alveolar septa (Fig. 7 ) (56, 57, 90) . Immunohistochemical staining has revealed numerous T-lymphocytes in such infiltrates (90) , while lavage fluids from Con A-treated animals contained significantly increased numbers of T-lymphocytes over those present in saline controls (103) , suggesting an amplifying process characterized by T-cell proliferation and/or recruitment into the lung. Mitogen-induced interstitial inflammation is reversible, and the lung lesions resolve completely within several days following cessation of aerosol challenge (57) .
Whereas antigen or mitogen aerosols, given individually, produce trivial or moderate interstitial inflammation, respectively, inhalation of antigen/T-cell mitogen mixtures by immune animals results in devastating pulmonary inflammation with areas of parenchymal necrosis and even infarction (57, 90, 104) (Fig. 8) . Occasionally, these are severe enough to cause death within hours of aerosol administration. These pulmonary lesions are characterized by interstitial edema and inflammatory infiltrates of neutrophils, lymphocytes, macrophages and basophils. Immunofluoresence microscopy has demonstrated inhaled antigen, specific antibody and C3 as granular interstitial deposits (Fig. 9) , at or near necrotic foci in the lung; such deposits were not observed in animals challenged with antigen or mitogen alone (57, 82, 104) . Repetitive weekly challenges with antigen/ mitogen aerosols produce chronic pulmonary injury characterized by areas of focal scarring and interstitial fibrosis (57) (Fig. 10) .~~~r~~~~~~V These observations thus demonstrate two pathogenic effects of these phytomitogens. First, they induce interstitial pulmonary inflammation when inhaled, even in an unimmunized host. Second, they trigger formation of pathogenic immune complexes between inhaled antigen, humoral antibody and complement. Since Con A is known to activate T-lymphoctes (and, in some instances, basophils as well) in a polyclonal fashion in vitro, we have proposed that its unusual toxicity for the lung results from its ability to activate these cells in vivo, again in an amplified, polyclonal fashion (90) . We further suggest that, whereas under usual circumstances inhaled antigen normally does not come into direct contact with humoral antibody, probably because the type I pneumocytes serve as an effective anatomic barrier (Fig. lla) , mediators released by mitogenstimulated lung lymphocytes and macrophages may alter or disrupt this barrier (Fig. llb) , thereby enhancing interactions between intra-alveolar antigen and interstitial/intravascular antibody (Fig. 1 hc) . Formation of immune complexes, accompanied by complement activation, then results in chemotactic attraction of neutrophils into the interstitial spaces (57) where, through release of proteolytic enzymes and, possibly, oxygen radicals, the collagen and elastin structural framework is destroyed, resulting in necrosis or dissolution of tissue structure.
To test the hypothesis that inhaled mitogens initiate or "trigger" immune complex formation between inhaled antigen and circulating antibody, Shenker et al. (104, 105) blocked the responsiveness of lymphocytes to T-cell mitogens in vivo by parenteral administration of cholera toxin. Such treatment elevated the cAMP levels of peripheral blood lymphocytes and blocked their proliferative responses to subsequent stimulation by Con A in vitro. It also inhibited the tuberculinlike response to intradermal injections of Con A, but did not affect the immune complex-mediated cutaneous Arthus vasculitis (104, 105) , thereby demonstrating a selective inhibition of cell-mediated reactions. If immune complex formation in the lung is dependent upon initiation by mitogen-activated leukocytes, it may be predicted that cholera toxin should inhibit both the mitogeninduced interstitial inflammation and immune complexmediated parenchymal necrosis. The hypothesis was supported by the experimental data; both forms of pulmonary inflammation were prevented by cholera toxin administration (104, 105) . Not only did these experiments provide critical support for the role of mitogens in "triggering" immune complex formation in the lung, they further suggested that individual susceptibility to environmental lung disease may depend, in part, on the inherent responsiveness of an individual's leukocytes to mitogen activation (104) .
This conceptual argument was further strengthened by Hollingdale et al. (104, 106) , who showed that decomplementation with purified cobra venom factor (CVF) [which lowered serum complement (CH50) hemolytic titers by 80% and lowered C3 concentrations by 82%] markedly inhibited the cutaneous Arthus vasculitis without affecting the cutaneous inflammatory response to Con A. As expected, CVF also prevented the production of immune complex-mediated parenchymal (Fig. 12) . Dose-response studies have indicated that inhalation of approximately 100 pug of LPS into the lung for each of three consecutive days results in a severe interstitial inflammation, while inhalation of lesser amounts (10-33 ,ug) results in little or no inflammation. Moreover, inhalation of LPS also results in a slightly delayed febrile response, generally reaching a maximal value 2-4 hr post aerosol (103) . Of particular interest, however, is our preliminary finding that LPS does not trigger immune complex injury when administered in conjunction with specific antigen to immunized animals, even though it produces an interstitial pneumonitis fully as severe as that produced by Con A. Thus, initiation of pulmonary immune complex formation by Con A must not represent merely the effects of a nonspecific injury to the alveolar interstitium, but instead must result from some relatively specific property of this lectin in the lung. An obvious possibility is that it may activate intrapulmonary T-cells to release vascular permeability factor (109), or mast cells and basophils to release vasoactive amines (36) , thereby increasing vascular permeability. Alternatively, it may serve as a particularly effective stimulus for local generation of AGEPC or of oxygen-derived free radicals. Regardless of the exact effector system(s) involved, the important point is that, while all polyclonal cell activators which we have tested to date are capable of causing pulmonary interstitial inflammation, some, but not all, also act to trigger local immune complex formation under the appropriate circumstances.
In order to determine whether mitogen-induced lung injury is mediated through release of soluble mediators by mitogen-activated cells, it is first necessary to characterize such mediators in vitro, in order to facilitate their subsequent identification in bronchopulmonary lavage fluids. As a first step, we have generated and characterized two rabbit lymphokines, lymphotoxin (LT) and mitogenic factor (MF), together with a monokine, IL-1. [MF appears to be identical to Interleukin 2(IL-2).] These mediators were selected in part because they can be readily measured in a quantitative and reproducible fashion. In addition, MF represents an endogenous mitogen thought to play an important role in the amplification of host immune effector responses (110) , while IL-1 is generally believed to serve as a central mediator in the acquisition and expression of cellular immune effector systems and, in particular, exerts an important (and, possibly, critical) role in cellular responses to exogenous mitogens (32) . The physicochemical properties of these rabbit mediators are given in Table 3 .
Recently, we have found both IL-1 as well as a LT-like factor in lavage fluid from animals challenged with LPS aerosols (103) . Thus, we suggest that IL-1 can be released in vivo following activation of alveolar macrophages by inhaled mitogen, and that IL-1 so released plays a central role in the production of fever, interstitial inflammation and even the "adjuvant" effects associated with allergic alveolitis in man. Recently, it has been shown that B-cells from such patients are more responsive to stimulation by IL-1 than are cells from control cohorts (9) .
If polyclonal activation of pulmonary leukocytes by inhaled mitogens is indeed relevant to human environmental lung disease, than at lease some environmental dusts known to cause lung disease should, in turn, In contrast, inhaled mitogens (closed circles) can activate lymphocytes in a polyclonal fashion, thus resulting in a significant local inflammatory response. Direct activation of intrapulmonary lymphocytes and, in some cases, of alveolar macrophages as well, results in local mediator release which further amplifies the local inflammatory process, and may also alter tight cellular junctions between Type I pneumocytes and possibly endothelial cell junctions in addition. Although accessibility of intraalveolar substances to circulating antibody is now greatly enhanced, no immune complexes form in the absence of inhaled antigen. (c) When immune individuals inhale mixtures of antigen and mitogen (or when the dust particles possess both antigenic and mitogenic properties), leukocytes are first activated to release mediators which, in turn, promote formation of immune complexes between intraalveolar antigen and circulating antibody Complement is then activated, leading to neutrophil recruitment, lysosomal enzyme release and oxygen-derived free-radical generation. Necrotizing injury and subsequent fibrosis results from enzymatic destruction of the collagen, basement membrane and elastin framework of the pulmonary interstitium. (Abbreviations: VPF, vascular permeability factor; LT, lymphotoxin; CF, lymphocyte-derived chemotactic factor; MAF, macrophage-activating factor; MIF, macrophage migration inhibitory factor; LAF, lymphocyte activating factor, also known as IL-1; EP endogenous pyrogen, now thought to be identical to LAF; AGEPC, acetyl glyceryl ether phosphorylcholine, the chemical name for platelet activating factor).
possess polyclonal cell-activating properties. Studies from our laboratory and from Burrell's laboratory (107) have shown that the causative agent for farmer's lung, M. faeni, is mitogenic for B-lymphocytes from immunologically naive or even germ-free animals (103) and that it also stimulates macrophages to release IL-1 (103). Moreover, M. faeni skin tests are known to be of little value, since they often give "false positive" reactions in nonimmune individuals (7) (as do Con A and PHA). Thus, this organism may indeed be acting as a polyclonal activator in man. In a rather different pulmonary disorder, byssinosis, respiratory symptoms are caused by an agent in respirable cotton dust which is thought by some to be LPS (108), a known B-cell mitogen and macrophage activator (35) .
Since there are many different organic and inorganic substances present in the environment which are known to be mitogenic (Table 2) , the potential role of polyclonal cell activation as a cause of environmental lung disease deserves serious consideration. Far from simply being "toxic" agents which cause "nonspecific" injury, they activate cells by binding to specific receptors; thus, their apparent lack of specificity, as compared to antigenic stimulation, simply reflects the widespread distri- of environmental lung disease can be viewed as the consequence of an inappropriate activation of normal inflammatory effector mechanisms. At the same time, it is well known that attempts to control inflammatory diseases by blocking one or more of the effector systems frequently extract a price of their own, such as increased susceptibility to infection.
Antigen inhalation almost certainly occurs in an ongoing fashion; it probably constitutes a major means for establishing "natural" host immunity, and only infrequently is associated with inflammatory lung disease. Thus, the antigenicity of an inhalant should not imply that it will necessarily cause pulmonary injury, nor, for that matter, should the presence of host immunity to that inhalant. Recognition that inhaled environmental substances possess mitogenic or polyclonal leukocyte-activating properties, on the other hand, should be a cause for concern. If, indeed, the in vivo pathogenicity of environmental mitogens parallels their in vitro activating properties, as is the case with Con A and LPS, then it should be possible to screen environmental dusts for mitogenic activity as a measure of their disease-causing potential. At the same time, one might be able to also screen inhabitants of that environment for disease susceptibility, by determining the responsiveness of their leukocytes to mitogenic stimulation in vitro, using appropriate dust mitogens.
